Close button
The Guardian
Email YouTube Facebook Instagram Twitter WhatsApp

How Amatem Forte softgel reduces malaria resistance, treatment failures

Related

Malaria Parasite

Poised to reduce the prevalence of malaria in the country, Elbe Pharma Nigeria Limited, has officially presented the outcome of the successful clinical trial on Amatem Forte Softgel capsules, conducted at Lagos State University Teaching Hospital (LASUTH), Ikeja, Lagos.

This has been described as an innovative antimalarial, with superior benefits for the patients compared to the conventional Artemether-Lumefantrine in tablet dosage form.

Two years ago, Elbe Pharma’s quest to find a superior, more acceptable antimalarial lead to the introduction of research-based formulation – Amatem forte softgel.

x

At the official unveiling and seminar on preventing treatment failure with Artemether-Lumefantrine, participants commended Elbe Pharma Nigeria limited for bridging the gap in the treatment of malaria, as the soft gel is the first of its kind in the country.

Speaking on the findings of a comparative study conducted on the bioavailability, efficacy and toxicity of Amatem Forte Softgel and a known brand of Artemether-Lumefantrine tablet formulation by a group of renowned researchers from LASUTH, Dr. Omoniyi Yemitan, noted: “Amatem Softgel was found to be more bioavailable in the bloodstream than the tablet formulation of Artemether-Lumefantrine.

The implication is that Amatem Softgel has a faster onset of action and more efficacious than tablets formulation”. He further disclosed that the toxicity study of Amatem Softgel did not reveal any major side effects of the drug on patients.

Key players in the healthcare sector opined the need to accommodate such innovative, patient-friendly therapy in the essential drug formulary and to be easily accessible in all the three tiers of the health care delivery system in Nigeria, in order to benefit the general populace from the dreaded scourge of malaria.


Receive News Alerts on Whatsapp: +2348136370421

No comments yet